Inpharma 1391 - 14 Jun 2003

■ BNP 1350* shows antitumour activity in patientswith refractory or relapsed non-small-cell lung cancer(NSCLC), according to data presented at the 39thAnnual Meeting of the American Society of ClinicalOncology, which was held recently in Chicago, US.This phase II study involved a total of 49 evaluablepatients with refractory or relapsed advanced NSCLCwho received BNP 1350. Among the evaluablerefractory population, 4% had a partial response and48% experienced disease stabilisation. Correspondingvalues among the evaluable relapsed patients were 4%and 35%, respectively. The median survival was 5.6months in the refractory patient group and 11.7months in the relapsed patient group. The mostfrequently observed side effect of BNP 1350 wasreversible bone marrow suppression.* BioNumerik Pharmaceuticals; phase II

BioNumerik Pharmaceuticals Inc, et al. CALGB Presents Clinical Results onBioNumerik Pharmaceuticals′ Novel Antitumor Agent at the 39th AnnualMeeting Of The American Society of Clinical Oncology (ASCO). MediaRelease : 2 Jun 2003. Available from: URL: http://www.bionumerik.com 809021660

1

Inpharma 14 Jun 2003 No. 13911173-8324/10/1391-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved